WS #16822
Novo Nordisk has upgraded its full-year guidance, citing continued robust demand for its GLP-1 weight-loss and diabetes treatments, Wegovy and Ozempic. The company highlighted that the pill version of Wegovy is gaining traction, expanding the addressable market. This positive outlook reinforces the structural growth narrative for the obesity treatment sector, providing a bullish anchor for healthcare stocks amidst broader market volatility driven by political shifts.
Novo Nordisk GLP-1 Demand
Novo Nordisk has upgraded its full-year guidance, citing continued robust demand for its GLP-1 weight-loss and diabetes treatments, Wegovy and Ozempic. The company highlighted that the pill version of Wegovy is gaining traction, expanding the addressable market. This positive outlook reinforces the structural growth narrative for the obesity treatment sector, providing a bullish anchor for healthcare stocks amidst broader market volatility driven by political shifts.